Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria. Opioid use disorder (OUD) can involve misuse of prescribed opioid medications, use of diverted opioid medications, or use of illicitly obtained heroin. OUD is typically a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality. In patients with OUD who have achieved abstinence through medically supervised withdrawal or by other means, maintenance treatment aims to prevent relapse. Options for long-term maintenance treatment include an opioid agonist (i.e., methadone or buprenorphine), an opioid antagonist (naltrexone), or non-medication, abstinence-based treatment.
Market Dynamics
Increasing incidences of pain associated with chronic diseases such as cancer, rising cases of opioid addiction, and increasing adoption of inorganic growth strategies by key players in order to expand their product portfolio in the global opioid use disorder market. The general population nowadays suffers from a wide range of chronic and severe health conditions, such as pain arising from injuries or cancer. They often result in chronic pain and in such cases, patients are given painkillers, especially opioids. While they help in lowering pain, they can cause addiction among patients. The abrupt discontinuation or higher dependency on these drugs leads to withdrawal symptoms. This further increases the chances of fatal consequences, such as deaths.
For instance, The American Psychiatric Association (APA), stated that approximately 72,000 Americans died due to opioid overdose in 2017. These factors are likely to drive the opioid use disorder market growth in the near future.
Key features of the study:
- This report provides in-depth analysis of the global opioid use disorder market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global opioid use disorder market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global opioid use disorder market
Detailed Segmentation:
- Global Opioid Use Disorder Market, By Drug Type:
- Buprenorphine
- Methadone
- Naltrexone
- Others
- Global Opioid Use Disorder Market, By Route of Administration:
- Global Opioid Use Disorder Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Opioid Use Disorder Market, By Region:
- North America
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- Buprenorphine
- Methadone
- Naltrexone
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Indivior PLC *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Pfizer, Inc.
- Hikma Pharmaceuticals PLC
- Camurus
“*” marked represents similar segmentation in other categories in the respective section.
